Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1974 Jun;53(6):1578-87.
doi: 10.1172/JCI107708.

Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia

Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia

J A Charlesworth et al. J Clin Invest. 1974 Jun.

Abstract

Metabolic studies using radioiodine-labeled third component of complement (C3) and the glycine-rich beta glycoprotein (GBG), a major component of the C3b-feedback pathway, were undertaken in normal subjects, in 22 patients with evidence of complement activation, and in 11 patients with various renal diseases without evidence of complement activation. In seven normal subjects GBG was found to be a rapidly metabolized protein with catabolic rates ranging from 1.7% to 2.2% of the plasma pool/h, synthesis rates from 0.14 to 0.21 mg/kg per h. and extravascular/intravascular distribution ratios from 0.81 to 1.31. In patients with reduced plasma C3, both increased C3 fractional catabolic rates and reduced C3 synthesis rates were observed, and in some patients there was evidence of increased extravascular distribution of the protein. GBG catabolism was usually increased when there was evidence of C3 activation, presumably reflecting activation of the C3b-feedback; but GBG turnover was normal or only slightly accelerated in some patients with accelerated C3 catabolism and profound hypocomplementemia, suggesting that reduced C3 synthesis had limited activation of the C3b-feedback.

PubMed Disclaimer

References

    1. Clin Exp Immunol. 1972 Jul;11(3):311-20 - PubMed
    1. Int Arch Allergy Appl Immunol. 1966;29(2):185-9 - PubMed
    1. Clin Sci Mol Med. 1974 Feb;46(2):223-9 - PubMed
    1. Mayo Clin Proc. 1973 May;48(5):340-8 - PubMed
    1. J Clin Invest. 1973 Mar;52(3):634-44 - PubMed

MeSH terms